Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
CNBC Markets · Thu, 29 Oct 2026 11:24:38 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.”
Rule-based headline sentiment: Neutral
More Stocks headlines
AI build-out hits snag as Google and Microsoft put off raising capex forecasts— CNBC MarketsAlphabet earnings miss reflects first real sign that AI is taking a bite out of search— CNBC MarketsHegseth reportedly fires U.S. top military planner as Trump downplays Iran peace talks— CNBC MarketsKalshi valuation jumps to $40 billion in latest funding round— CNBC Markets